LOXO Oncology Competitors, Revenue and Alternatives
Navigation
Overview
Industry Ranking
State Ranking
Growjo 10k Ranking
Estimated Revenue & Financials
- LOXO Oncology's estimated annual revenue is currently $45M per year.
- LOXO Oncology received $294.8M in venture funding in June 2017.
- LOXO Oncology's estimated revenue per employee is $201,000
- LOXO Oncology's total funding is $125.3M.
Employee Data
- LOXO Oncology has 224 Employees.
- LOXO Oncology grew their employee count by 66% last year.
- LOXO Oncology currently has 6 job openings.
LOXO Oncology Competitors
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
| $8M | 40 | 5% | N/A | |
| $25.7M | 128 | 11% | N/A | |
| $25.7M | 128 | N/A | N/A | |
| $9.6M | 48 | N/A | N/A | |
| $169.4M | 843 | 27% | N/A | |
| $19.5M | 97 | N/A | N/A | |
| $15.3M | 76 | 9% | N/A | |
| $251.7M | 1252 | N/A | N/A | |
| $13.7M | 68 | 152% | N/A | |
| $45M | 224 | 66% | N/A |
What Is LOXO Oncology?
Loxo Oncology is a biopharmaceutical company dedicated to developing highly-selective medicines for patients with genomically defined cancers. Our pipeline is focused on treatments aimed at cancers caused by a single inappropriate DNA change, known as oncogenic drivers, which the tumor depends on for growth and survival. Loxo Oncology develops purpose-built medicines designed to selectively and potently inhibit these oncogenic drivers. We believe that this approach, combined with the use of tumor genomic testing to identify appropriate patients, will allow us to develop medicines that provide best-in-class disease control and safety and, ultimately, deliver on the promise of precision medicine. We are based in Stamford, CT with sites in San Francisco, CA and Boulder, CO. For more information about Loxo Oncology, please visit us at www.loxooncology.com.
keywords:Biotechnology,Healthcare,Pharmaceuticals224
Number of Employees
$45M
Revenue (est)
6
Current Jobs
66%
Employee Growth %
$125.3M
Total Funding
N/A
Valuation
N/A
Accelerator
B2B
Type
Executive Contacts
| Name | Title | |
|---|---|---|
| Steven Andrews | Vice President, Discovery Chemistry | Email Available |
| Nisha Nanda | VP Development Strategy | |
| Sara Slifka | Sara Slifka VP, Business Operations & Program Management | Email Available |
| Jonathan Katchmore | Director, Diagnostic Account Strategy | Email Available |
| Cindy Adduci | Senior Director Program Management | |
| Stacey Spencer | Associate Director, Cmc | Email Available |
| Christine Schrade | Executive Assistant Office Manager | |
| Mary Rosendahl | Principal Research Scientist | Email Available |
| Kristin Hopp | Biospecimen Manager | Email Available |
| Narasimha Marella | Director, Biomarker Operations | Email Available |
LOXO Oncology News
Developed by Eli Lilly and Co's Loxo Oncology and marketed by ... with oncologists and pharmaceutical and diagnostic industry executives.
One example is the drug Vitrakvi, developed by Eli Lilly and its Loxo Oncology, which is marketed by Bayer. Vitrakvi works on cancers where ...
The bigger the book-to-market ratio is, the more fundamentally cheap is the investigated company. Loxo Oncology, Inc. (LOXO) has a BTM ratio ...
LOXO Oncology Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2014-05-07 | $24.0M | B | New Enterprise Associates | Article |
| 2017-06-22 | $294.8M | Undisclosed | Morgan Stanley | Article |
LOXO Oncology Executive Hires
| Date | Name | Title | Reference |
|---|---|---|---|
| 2014-05-07 | Mikel Moyer | Chief Scientific Officer | Article |
| 2014-10-29 | Jennifer Low | Chief Medical Officer/EVP R/D | Article |